FDA Approves AMJEVITA — Nuvaila Limited
Nuvaila Limited has received FDA approval for the injection adalimumab-atto, a subcutaneous formulation of the brand drug Amjevita. This launch significantly expands the market for choice-based biologics in autoimmune care.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed